dc.contributor.author | Novychenko, Yuliia | |
dc.contributor.author | Khukhlina, Oksana | |
dc.contributor.author | Kovalenko, Svitlana | |
dc.contributor.author | Dudka, Inna | |
dc.date.accessioned | 2024-11-13T11:53:17Z | |
dc.date.available | 2024-11-13T11:53:17Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/25921 | |
dc.description.abstract | Abstract. The article describes the experience of practical use of Ukrainian drug Lipin (phosphatidylcholine (lecithin)) for the treatment of patients with pneumonias associated with COVID-19. The drug does not have any analogues at the market of phosphatidylcholines, possesses a strong anti-hypoxic action, promotes oxygen diffusion rate from the lungs into the blood and from the blood to the tissues, normalizes the processes of tissue respiration, restores functional activity of the endothelial cells, and improves microcirculation and rheological blood properties. | uk_UA |
dc.language.iso | en | uk_UA |
dc.publisher | PharmacologyOnLine (міжнародний онлайн-журнал) | uk_UA |
dc.subject | pneumonia | uk_UA |
dc.subject | COVID-19 | uk_UA |
dc.subject | treatment | uk_UA |
dc.subject | phosphatidylcholine | uk_UA |
dc.title | Effect of Lipin administration in a comprehensive treatment of community-acquired pneumonia associated with COVID-19 | uk_UA |
dc.type | Article | uk_UA |